-- 木曜午前遅く、米国預託証券(ADR)が上昇したことを受け、欧州株は米国市場で取引され、S&Pヨーロッパ・セレクトADR指数は2.20%高の1,818.51となった。 欧州大陸では、製薬会社のノボ・ノルディスク(NVO)と銀行のINGグループ(ING)がそれぞれ5.3%と4.9%上昇し、上昇を牽引した。これに続き、バイオ医薬品会社のグリフォルス(GRFS)と消費財会社のユニリーバ(UL)がそれぞれ3.2%と3.1%上昇した。 欧州大陸では、インターネット広告会社のクリテオ(CRTO)と通信会社のノキア(NOK)がそれぞれ3.2%と1.9%下落し、下落を牽引した。 英国では、クルーズ船運航会社のカーニバル(CUK)と公益事業会社のナショナル・グリッド(NGG)がそれぞれ4.8%と3.5%上昇し、上昇を牽引した。続いて、ロイズ・バンキング・グループ(LYG)と通信事業者ボーダフォン・グループ(VOD)がそれぞれ2.6%と2.3%上昇した。 英国とアイルランドの下落銘柄では、ソフトウェア企業のエンダバ(DAVA)とバイシクル・セラピューティクス(BCYC)がそれぞれ5.2%と2.3%下落した。これに続き、バイオ医薬品企業のアマリン(AMRN)とメレオ・バイオファーマ・グループ(MREO)がそれぞれ1.3%と0.9%下落した。
Related Articles
Research Alert: The Clorox Company Beats Estimates Driven By Household And International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CLX reported Q3 FY 26 net sales of $1.67B, flat Y/Y with organic sales down 1%, while adj. EPS of $1.64 grew 13% and beat consensus by $0.10. Gross margin contracted 140 bps to 43.2% due to elevated manufacturing costs and unfavorable mix, though disciplined expense management supported earnings. Mixed segment performance showed Household and International delivering growth of 3% and 8%, respectively, while Lifestyle declined 9% on lower consumption and inventory adjustments. Management updated FY 26 guidance expecting net sales to decline ~6% with organic sales down ~9%, including a 7.5%-pt ERP headwind. Adj. EPS guidance of $5.45-$5.65 represents a 27%-29% decline, with gross margin expected to contract 250-300 bps from GOJO inventory step-up and elevated energy costs. The April 1 GOJO acquisition expands the health portfolio though near-term integration costs pressure results. We believe the completed $580M digital transformation positions CLX for long-term operational improvements despite macro headwinds.
Research Alert: Rivn: Q1 Eps Ahead Of Consensus; 2026 Guidance Unchanged
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Rivian (RIVN) posted Q1 adjusted EPS of -$0.55 vs. -$0.41, ahead of the -$0.60 consensus. Revenue rose 11% to $1.38B ($10M ahead of consensus) on a 20% increase in total vehicle sales to 10,365 units, augmented by a 49% Y/Y increase in software and services revenue to $473M. RIVN's gross margin contracted 800 bps to 8.6%, but was ahead of the 8.4% consensus. The quarter's financial results reflect the company's strategic pivot toward broader market accessibility with the R2, though at the cost of near-term profitability. RIVN maintained prior 2026 guidance for adjusted EBITDA, vehicle deliveries, and capex. The company ended Q1 with cash of $4.8B, down from $6.1B at year-end 2025. Shares are trading 1% higher in after-hours trading. RIVN's Q1 earnings were ahead of expectations, although cash burn remains a key concern, with free cash flow deteriorating, driven by increased operating expenses and working capital consumption. Execution risks remain high given challenging demand facing the broader EV industry.
Tanger Q1 Core FFO, Revenue Rise; 2026 Guidance Increased
Tanger (SKT) reported Q1 core funds from operations late Thursday of $0.59 per diluted share, up from $0.53 a year earlier.Analysts polled by FactSet expected $0.58.Revenue in the three months ended March 31 rose to $150.4 million from $135.4 million a year earlier.Analysts surveyed by FactSet expected $142.9 million.The company raised 2026 FFO guidance to $2.42 to $2.50 per diluted share from $2.41 to $2.49.Analysts polled by FactSet expect $2.47.Tanger shares fell 2.3% in after-hours trading.